Safety, tolerability, dose-related heparin-neutralizing activity and pharmacokinetics of neutralase(TM) (heparinase I) in adult healthy males

被引：0
|
作者：
Recker, D [1 ]
Clementi, W [1 ]
McIntosh, C [1 ]
Broughton, R [1 ]
Zimmermann, J [1 ]
Lee, K [1 ]
机构：
[1] IBEX TECHNOL,MONTREAL,PQ,CANADA
来源：
ANESTHESIA AND ANALGESIA | 1997年 / 84卷
关键词：
D O I：
暂无
中图分类号：
R614 [麻醉学];
学科分类号：
100217 ;
摘要：
引用
收藏
页码：S123 / S123
页数：1
相关论文
共 50 条
  • [41] Phase I Single Ascending Dose and Food Effect Study in Healthy Adults and Phase I/IIa Multiple Ascending Dose Study in Patients with Pulmonary Tuberculosis to Assess Pharmacokinetics, Bactericidal Activity, Tolerability, and Safety of OPC-167832
    Dawson, Rodney
    Diacon, Andreas H.
    Narunsky, Kim
    De Jager, Veronique R.
    Stinson, Kelly W.
    Zhang, Xiaoyan
    Liu, Yongge
    Hafkin, Jeffrey
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2023, 67 (06)
  • [42] Safety, Tolerability, and Pharmacokinetics of Oral Nafithromycin (WCK 4873) after Single or Multiple Doses and Effects of Food on Single-Dose Bioavailability in Healthy Adult Subjects
    Iwanowski, Piotr
    Bhatia, Ashima
    Gupta, Mugdha
    Patel, Anasuya
    Chavan, Rajesh
    Yeole, Ravindra
    Friedland, David
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2019, 63 (12)
  • [43] An open-label, phase I, dose escalating study evaluating safety, tolerability and pharmacokinetics of oral administration of irinotecan in adult patients with solid tumors
    Palshof, J. A.
    Kumler, I.
    Sorensen, P. G.
    Jensen, B. V.
    Nielsen, D. L.
    ANNALS OF ONCOLOGY, 2018, 29 : 142 - 142
  • [44] Eye drops of Novel Synthetic Peptide for neovascular age related macular degeneration : Safety, tolerability and pharmacokinetics study in healthy volunteers (phase I study)
    Kwak, Hyunduck
    Ghim, Jong-Lyul
    Ahn, Byulnim
    Woo, Taegyu
    Kim, Suyeon
    Jang, Jin-Wook
    Cho, Yunseok
    Yang, Jaewook
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2023, 64 (08)
  • [45] A phase I trial of the safety, tolerability and pharmacokinetics of cannabidiol administered as single-dose oil solution and single and multiple doses of a sublingual wafer in healthy volunteers
    Hosseini, Adele
    McLachlan, Andrew J.
    Lickliter, Jason D.
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2021, 87 (04) : 2070 - 2077
  • [46] Safety, Tolerability, and Pharmacokinetics of Kukoamine B in Healthy Volunteers: A Randomized, Double-Blind, Placebo-Controlled, Multiple-Dose Phase I Study
    Qian Zhao
    Hongzhong Liu
    Zhenlei Wang
    Teng Wang
    Cheng Cui
    Huanhuan Wang
    Lili Li
    Wen Zhong
    Ji Jiang
    Kai Dong
    Shuai Chen
    Chunyan Jin
    Pei Hu
    Advances in Therapy, 2023, 40 : 3186 - 3198
  • [47] Safety, tolerability and pharmacokinetics of HS-10383 in healthy subjects: A randomized, doubleblinded, placebo-controlled and multiple dose-ascending phase I trial
    Li, Qian
    Chen, Ke-Guang
    Zhang, Ye-Hui
    Zhou, Hai-Yan
    Ye, Pan-Pan
    Song, Lin-Lin
    Zhao, Fu-Rong
    Shi, Jin-Yi
    Wu, Qiong
    Zhang, Jing
    Jia, Wen
    Kong, Kai-Meng
    Tao, Yu-Ying
    Yang, Xin-Mei
    Zhao, Wei
    RESPIROLOGY, 2024, 29 : 196 - 196
  • [48] Safety, Tolerability, and Pharmacokinetics of Kukoamine B in Healthy Volunteers: A Randomized, Double-Blind, Placebo-Controlled, Multiple-Dose Phase I Study
    Zhao, Qian
    Liu, Hongzhong
    Wang, Zhenlei
    Wang, Teng
    Cui, Cheng
    Wang, Huanhuan
    Li, Lili
    Zhong, Wen
    Jiang, Ji
    Dong, Kai
    Chen, Shuai
    Jin, Chunyan
    Hu, Pei
    ADVANCES IN THERAPY, 2023, 40 (07) : 3186 - 3198
  • [49] Phase I dose-escalation study evaluating safety, tolerability and pharmacokinetics of MEDI-573, a dual IGF-I/II neutralizing antibody, in Japanese patients with advanced solid tumours
    Haruo Iguchi
    Tomohiro Nishina
    Naoyuki Nogami
    Toshiyuki Kozuki
    Yumiko Yamagiwa
    Katsuro Yagawa
    Investigational New Drugs, 2015, 33 : 194 - 200
  • [50] Phase I dose-escalation study evaluating safety, tolerability and pharmacokinetics of MEDI-573, a dual IGF-I/II neutralizing antibody, in Japanese patients with advanced solid tumours
    Iguchi, Haruo
    Nishina, Tomohiro
    Nogami, Naoyuki
    Kozuki, Toshiyuki
    Yamagiwa, Yumiko
    Yagawa, Katsuro
    INVESTIGATIONAL NEW DRUGS, 2015, 33 (01) : 194 - 200
12345